Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, December 01, 2021 10:33:38 AM
https://www.israel21c.org/drug-saves-47-of-50-severe-covid-patients-in-trial/?utm_source=The+Weekly&utm_campaign=weekly-2021-12-01&utm_medium=email
Bonus BioGroup says its MesenCure experimental treatment resulted in 94% survival rate of trial subjects and cut hospitalization time in half.
By Abigail Klein Leichman NOVEMBER 25, 2021, 4:25 PM
Israel’s Bonus BioGroup reports a survival rate of 94 percent (47 of 50) of the severe Covid-19 patients treated with its drug product MesenCure in a Phase II, multicenter clinical trial.
Study results, soon to be published, show MesenCure treatment reduced study participants’ hospitalization period by about half compared to a control group. All these patients had life-threatening pneumonia and respiratory distress caused by Covid-19.
The data shows that MesenCure treatment reduced mortality by about 70% compared with the control group. Only two of the first 30 severe Covid-19 patients treated with MesenCure died due to Covid-19 or its complications, while 14 of 60 similar patients in the control group died.
MesenCure treatment shortened the hospitalization period of severe Covid-19 patients by eight days on average, a reduction of 45% relative to the control group.
The experimental group included women and men aged 41.4 to 77.4. About 77% of the severe Covid-19 patients treated in three hospitals with MesenCure had one or more risk factors for poor prognosis: hypertension, hyperlipidemia, obesity and Type 2 diabetes. Most were treated during the fourth Covid-19 wave in Israel, dominated by the Delta strain.
The control group received the current standard of care — anti-inflammatory drugs in combination with steroids. This regimen, according to Bonus BioGroup, reduces mortality in hospitalized Covid-19 patients only slightly, from 25.8% to 21.8%, indicating that MesenCure is four times more effective.
“We are proud of our success in leading the world to be a safer place by developing a medication for severe Covid-19 patients, thereby dramatically reducing the threat to their lives,” said Dr. Shai Meretzki, CEO of Bonus BioGroup.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM